60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report sent to investors on Friday morning,Benzinga reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Saturday, March 22nd.

60 Degrees Pharmaceuticals Price Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $1.86 on Friday. The stock’s 50-day moving average is $2.61 and its 200-day moving average is $4.62. 60 Degrees Pharmaceuticals has a one year low of $1.41 and a one year high of $35.99. The firm has a market cap of $2.74 million, a price-to-earnings ratio of -0.18 and a beta of 4.52.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.